1. Home
  2. TRBG vs VRCA Comparison

TRBG vs VRCA Comparison

Compare TRBG & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRBG

TurboGen Ltd. Ordinary Shares

N/A

Current Price

$3.51

Market Cap

87.2M

Sector

Utilities

ML Signal

N/A

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$3.85

Market Cap

88.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRBG
VRCA
Founded
2014
2013
Country
Israel
United States
Employees
20
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.2M
88.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
TRBG
VRCA
Price
$3.51
$3.85
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $13.83
AVG Volume (30 Days)
48.6K
★ 48.7K
Earning Date
09-24-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $35,577,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$58.01
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 370.22
52 Week Low
$3.13
$3.28
52 Week High
$5.84
$9.82

Technical Indicators

Market Signals
Indicator
TRBG
VRCA
Relative Strength Index (RSI) 37.00 45.96
Support Level $3.50 N/A
Resistance Level $3.78 $5.94
Average True Range (ATR) 0.23 0.35
MACD 0.06 -0.00
Stochastic Oscillator 43.93 54.90

Price Performance

Historical Comparison
TRBG
VRCA

About TRBG TurboGen Ltd. Ordinary Shares

Turbogen Ltd is engaged in developing multifuel CHP systems with a vision of providing on-site energy for buildings. Its CHP systems outperform current electric efficiency solutions, enabling fast ROI, lower building emissions, and peak saving for utilities. The company's multi-fuel technology enables hybrid Operations: Solar-Gas, Hydrogen-Gas, SOFC-Gas.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: